U.S. Markets open in 6 hrs 47 mins

Therapix Biosciences Ltd. (TRPX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3170-0.3130 (-49.68%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6300
Open0.3626
Bid0.0000 x 3000
Ask0.0000 x 2200
Day's Range0.3012 - 0.3990
52 Week Range0.2520 - 3.2430
Volume7,099,253
Avg. Volume1,992,606
Market Cap4.466M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Therapix Biosciences Announces OTC Pink Ticker Symbol 'TRPXY' and Removal of Injunction by Israeli Court
    PR Newswire

    Therapix Biosciences Announces OTC Pink Ticker Symbol 'TRPXY' and Removal of Injunction by Israeli Court

    Therapix Biosciences Ltd. (OTC Pink: TRPXY) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that its American Depositary Shares ("ADSs") will now trade under the OTC Pink ticker symbol "TRPXY." The Company also announced the removal by an Israeli court of a previously reported temporary injunction against the Company prohibiting the Company from making any changes in its share capital or adopting any resolution which is not in the ordinary course of business.

  • Therapix Biosciences Receives Notice of Delisting and Injunction from Israeli Court
    PR Newswire

    Therapix Biosciences Receives Notice of Delisting and Injunction from Israeli Court

    Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today receipt of Notice of Delisting and Injunction from Israeli Court.

  • Therapix Biosciences Raises $2.6 Million in Private Placement
    PR Newswire

    Therapix Biosciences Raises $2.6 Million in Private Placement

    Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced that it has entered into definitive agreements with several accredited and institutional investors providing for the issuance of an aggregate of 5.2 million American Depositary Shares ("ADSs") at a purchase price of $0.50 per ADS, and warrants to purchase up to 2.6 million American Depositary Shares in a private placement (the "Warrants," and together with the ADSs: the "Securities").